Soluble ZcytoR14 Receptor for Dual IL-17A and IL-17F Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune-related and inflammatory diseases, such as rheumatoid arthritis and asthma, are limited in effectively targeting the pro-inflammatory cytokines IL-17A and IL-17F, as they often require therapies that target individual cytokines separately, lacking comprehensive solutions for their shared biological pathways.
Innovation Solution
Identification of ZcytoR14 as a receptor for IL-17F, which binds both IL-17A and IL-17F with high affinity, allowing for the development of soluble ZcytoR14 receptors and neutralizing antibodies that can block or neutralize both cytokines, providing a therapeutic approach to treat inflammatory diseases by targeting both IL-17A and IL-17F simultaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If therapies target individual cytokines (IL-17A or IL-17F) separately, then treatment specificity is improved, but therapeutic comprehensiveness deteriorates
Solution Approach 1:
The patent applies universality by engineering a chimeric receptor (ZcytoR14) that combines ligand-binding domains from IL-17R and IL-17FR to enable a single receptor to bind both IL-17A and IL-17F cytokines. This multi-functional receptor provides comprehensive therapeutic coverage while maintaining treatment specificity through engineered binding properties.
2Adaptability or versatility
If soluble ZcytoR14 receptors are used to block both IL-17A and IL-17F, then therapeutic comprehensiveness is improved, but treatment mechanism complexity increases
Solution Approach 1:
The patent employs an intermediary approach by creating a soluble chimeric ZcytoR14 receptor that acts as a mediator between the two cytokine signaling pathways. This single soluble receptor intermediate simultaneously intercepts both IL-17A and IL-17F, simplifying the therapeutic mechanism compared to using separate agents for each cytokine.
3Strength
If neutralizing antibodies against ZcytoR14 are developed, then binding affinity is improved, but development complexity increases
Solution Approach 1:
The patent applies copying by creating a soluble version of the chimeric ZcytoR14 receptor that replicates the binding properties of the membrane-bound receptor. This soluble copy serves as an ideal target for antibody development, allowing high-affinity neutralizing antibodies to be generated against a well-defined, accessible target structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of ZcytoR14 receptors and antibodies effectively blocks or neutralizes IL-17A and IL-17F activity, offering a more comprehensive therapeutic strategy for inflammatory diseases by addressing the shared pathways of these cytokines, potentially leading to improved treatment outcomes for conditions like rheumatoid arthritis and asthma.
Implementation Method 1
ZcytoR14 as a receptor for IL-17F, which binds both IL-17A and IL-17F with high affinity
Implementation Method 2
neutralizing anti-ZcytoR14 antibodies that can block or neutralize both cytokines
Data Source
AI summary
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.